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A B S T R A C T
Coronavirus Disease 2019 (COVID-19) is an ongoing public health emergency and new knowledge about its
immunopathogenic mechanisms is deemed necessary in the attempt to reduce the death burden, globally. For the
first time in worldwide literature, we provide scientific evidence that in COVID-19 vasculitis a life-threatening
escalation from type 2 T-helper immune response (humoral immunity) to type 3 hypersensitivity (immune complex
disease) takes place. The subsequent deposition of immune complexes inside the vascular walls is supposed to
induce a severe inflammatory state and a cytokine release syndrome, whose interleukin-6 is the key myokine,
from the smooth muscle cells of blood vessels.
Coronavirus Disease 2019 (COVID-19) is an ongoing public health
emergency around the world and the acquisition of new knowledge
about its immunopathogenesis is required in the attempt to reduce the
death burden, globally. As well known, naїve T-helper cells (Th0) can
detect pathogens never encountered before, like the specific case of
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the
etiological agent responsible for the disease, able to infect the human
cells via angiotensin-converting enzyme 2 receptors [1]. Classically, on
the basis of the novel infectious agent, Th0 polarize the immune response
into type 1 T-helper (Th1), the default response in immunocompetent
subjects to intracellular or phagocytosable pathogens (e.g. viruses, bac-
teria, protozoa, fungi) and mediated by macrophages and T-cytotoxic
(Tc) cells (cell-mediated immunity), or into type 2T-helper (Th2), typically
directed against extracellular non-phagocytosable pathogens, for in-
stance helminths, and whose main effectors are eosinophils, basophils
and mastocytes, as well as B cells (humoral immunity) [2]. The ultimate
goal of humoral immunity is to produce opsonising antibodies and to
generate memory cells able to promptly counteract the pathogen in the
future, if necessary [3]. During our researches on COVID-19, we have
disclosed that, for reasons still unclear and maybe related to the viral
load or to Th1 and Tc breakdown, the immune system is forced to mount
a Th2 response against SARS-CoV-2 in patients requiring intensive care,
rather than a Th1 response, which would keep the infection under control
by means of macrophages and Tc cells [4]. According to Gell and Coombs
classification, type 3 hypersensitivity takes place when an excess or slight
excess of soluble antigens lead to the accumulation of immune com-
plexes, not enough cleared from the circulation by the innate immune
system [5]. These antigen-antibody complexes precipitate inside the
tissues, in particular blood vessels, inducing a severe inflammatory state
by the action of complement anaphylatoxins (C3a and C5a), which in
turn stimulate the release of histamine from mast cells and the recruit-
ment of phagocytes, in primis neutrophils, the main responsible for the
tissue damage [5]. On histopathology, the result of this process inside the
walls of blood vessels is depicted by an acute necrotizing vasculitis with
neutrophilic infiltration, karyorrhexis and fibrinoid necrosis, the so
called «leukocytoclastic vasculitis» (LCV), also reported in the English
medical literature by the term «hypersensitivity vasculitis» [6]; platelet
aggregation correlates with hypercoagulability and thrombosis, disorders
described in course of COVID-19, too [7]. The just mentioned fibrinoid
necrosis represents a specific pattern of tissue injury, which occurs once
antigen-antibody complexes are deposited in the walls of blood vessels
along with fibrin and complement anaphylatoxins; therefore, it can be
considered a diagnostic clue of immune-mediated vasculitides from type
3 hypersensitivity [8]. LCV is preceded by a viral infection, such as he-
patitis B, hepatitis C and HIV, in a relevant percentage of cases [6]. The
onset time of type 3 hypersensitivity varies from days to weeks de-
pending on the presence or not of memory cells against the precipitating
antigen; clinical features emerge approximately 10 days after initial an-
tigenic challenge [8]. During the Severe Acute Respiratory Syndrome
(SARS) outbreak in 2002–2003, caused by SARS-CoV-2 predecessor
(SARS-CoV), it was observed that the acute respiratory distress syn-
drome, one the most serious complications of the disease, significantly
overlapped with antiviral immunoglobulin G (IgG) seroconversion [9];
besides, it was found that patients who developed more quickly the anti-
spike neutralizing antibody showed a higher risk of dying from the dis-
ease [10]. Translating our current findings on COVID-19, these alarming
data can be now explained for the first time in worldwide literature by a
life-threatening escalation from Th2 immune response to type 3 hy-
persensitivity with the subsequent deposition of antigen-antibody com-
plexes, particularly inside the walls of blood vessels, to such an extent as
to generate a systemic vasculitis in the context of an immune complex
disease (Fig. 1). This event is accompanied by complement C3 activation,
which is positioned upstream of the thrombo-inflammatory complement
cascade in COVID-19; therefore, to prevent C3 activation into C3a ana-
phylatoxin through specific inhibitors, like compstatin-based AMY-101,
can provide effective therapeutic results [11]. Preexisting endothelial
dysfunctions due to atherosclerosis could worsen the deposition process
in elderly and middle-aged patients [12]; since the smooth muscle cells
in tunica media of blood vessels are able to produce interleukin-6 (IL-6)
[13], a key myokine of inflammation and of the cytokine release syn-
drome, their inflammatory involvement can justify well the described
«cytokine storm» in COVID-19 critical patients, a dramatic phenomenon
remained not fully elucidated up to date.
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Fig. 1. Ileal and splenic infarctions in a 72-year-old Italian male patient affected by COVID-19 and submitted to rescue surgery after 18 days from SARS-CoV-2
molecular detection through nasopharyngeal swab [IL-6 sequential dosages by serum immune assays: from 154.03 ρg/ml - day 1 to 2656.46 ρg/ml - day 18]: on
sagittal abdomen computed tomography (CT) scan with contrast medium, an aortic thrombus (A, red arrow) and one at the celiac tripod (A, yellow arrow) are clearly
visible, while on axial abdomen CT scans a large ischemic intestinal loop shows pneumatosis intestinalis (A, green arrow) and only a central portion of healthy spleen
(A, blue arrow) remains vascularized by the splenic artery; grossly, the transition zone between the upper residual spleen parenchyma and the lower discolored
infarcted area is captured (B); on histopathology, the splenic artery appears thrombosed and involved by vasculitis (C, hematoxylin & eosin, 2.5× objective); at
higher magnification (D, hematoxylin & eosin, 10× objective), the inflammation is arranged around (periarteritis) and inside (panarteritis) the vascular wall; in the
cytological details, neutrophils and karyorrhexis are well noticeable, a classical histological picture for LCV (E, hematoxylin & eosin, 60× objective), while Toluidine
blue stain highlights the purple granules of a mast cell in the degranulation phase close to polymorphonuclear neutrophils (F, 100× objective); phosphotungstic acid
hematoxylin reveals blue spots of fibrinoid necrosis in the full thickness of the splenic artery wall (G, 40× objective), more concentrated just below the internal
elastic membrane in the innermost part of tunica media (H, 100× objective); immunofluorescence confirms the presence of green-brightened immune complexes,
mainly consisting of IgG (I, anti-human polyclonal IgG/FITC, 100× objective), but also of IgM (J, anti-human polyclonal IgM/FITC, 100× objective) and IgA (K,
anti-human polyclonal IgA/FITC, 100× objective), together with C3 complement deposits (L, anti-human polyclonal C3 complement/FITC, 100× objective). (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
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